INTRODUCTION: The formation of diabetic ulcers (DU) is a common complication for diabetic patients resulting in serious chronic wounds. There is therefore, an urgent need for complex treatment of this problem. This study examines a bioactive wound dressing of a biodegradable electrospun nanofibrous blend of poly(L-lactide-co-ε-caprolactone) and poly(ε-caprolactone) (PLCL/PCL) covered by a thin fibrin layer for sustained delivery of bioactive molecules. METHODS: Electrospun PLCL/PCL nanofibers were coated with fibrin-based coating prepared by a controlled technique and enriched with human platelet lysate (hPL), fibroblast growth factor 2 (FGF), and vascular endothelial growth factor (VEGF). The coating was characterized by scanning electron microscopy and fluorescent microscopy. Protein content and its release rate and the effect on human saphenous vein endothelial cells (HSVEC) were evaluated. RESULTS: The highest protein amount is achieved by the coating of PLCL/PCL with a fibrin mesh containing 20% v/v hPL (NF20). The fibrin coating serves as an excellent scaffold to accumulate bioactive molecules from hPL such as PDGF-BB, fibronectin (Fn), and α-2 antiplasmin. The NF20 coating shows both fast and a sustained release of the attached bioactive molecules (Fn, VEGF, FGF). The dressing significantly increases the viability of human saphenous vein endothelial cells (HSVECs) cultivated on a collagen-based wound model. The exogenous addition of FGF and VEGF during the coating procedure further increases the HSVECs viability. In addition, the presence of α-2 antiplasmin significantly stabilizes the fibrin mesh and prevents its cleavage by plasmin. DISCUSSION: The NF20 coating supplemented with FGF and VEGF provides a promising wound dressing for the complex treatment of DU. The incorporation of various bioactive molecules from hPL and growth factors has great potential to support the healing processes by providing appropriate stimuli in the chronic wound.

Departament de Biologia Cellular Fisiologia i Immunologia Universitat Autonoma de Barcelona Bellaterra Spain

Department of Biomaterials and Tissue Engineering Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Department of Chemistry and Physics of Surfaces and Biointerfaces Institute of Macromolecular Chemistry Czech Academy of Sciences Prague Czech Republic

Department of Chemistry Technical University of Liberec Liberec Czech Republic

Zobrazit více v PubMed

Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg. 2004;187(5):S38–S43. doi:10.1016/S0002-9610(03)00303-9 PubMed DOI

Martino MM, Briquez PS, Maruyama K, Hubbell JA. Extracellular matrix-inspired growth factor delivery systems for bone regeneration. Adv Drug Deliv Rev. 2015;94:41–52. doi:10.1016/j.addr.2015.04.007 PubMed DOI

Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018;1411(1):153–165. doi:10.1111/NYAS.13569 PubMed DOI PMC

Zubair M, Ahmad J. Role of growth factors and cytokines in diabetic foot ulcer healing: a detailed review. Rev Endocr Metab Disord. 2019;20(2):207–217. doi:10.1007/S11154-019-09492-1 PubMed DOI

Khan A, Morsi Y, Zhu T, et al. Electrospinning: an emerging technology to construct polymer-based nanofibrous scaffolds for diabetic wound healing. Front Mater Sci. 2021;15(1):10–35. doi:10.1007/S11706-021-0540-1 DOI

Woodruff MA, Hutmacher DW. The return of a forgotten polymer—Polycaprolactone in the 21st century. Prog Polym Sci. 2010;35(10):1217–1256. doi:10.1016/J.PROGPOLYMSCI.2010.04.002 DOI

Miguel SP, Sequeira RS, Moreira AF, et al. An overview of electrospun membranes loaded with bioactive molecules for improving the wound healing process. Eur J Pharm Biopharm. 2019;139:1–22. doi:10.1016/J.EJPB.2019.03.010 PubMed DOI

Bonferoni MC, Rossi S, Sandri G, et al. Bioactive medications for the delivery of platelet derivatives to skin wounds. Curr Drug Deliv. 2019;16(5):472–483. doi:10.2174/1381612825666190320154406 PubMed DOI PMC

O’Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen. 2008;16(6):749–756. doi:10.1111/J.1524-475X.2008.00426.X PubMed DOI

Sovkova V, Vocetkova K, Rampichova M, et al. Platelet lysate as a serum replacement for skin cell culture on biomimetic PCL nanofibers. Platelets. 2017;29(4):395–405. doi:10.1080/09537104.2017.1316838 PubMed DOI

Chiara Barsotti M, Losi P, Briganti E, et al. Effect of platelet lysate on human cells involved in different phases of wound healing. PLoS One. 2013;8(12):e84753. doi:10.1371/journal.pone.0084753. PubMed DOI PMC

Jafar H, Hasan M, Al-Hattab D, et al. Platelet lysate promotes the healing of long-standing diabetic foot ulcers: a report of two cases and in vitro study. Heliyon. 2020;6(5):e03929. doi:10.1016/J.HELIYON.2020.E03929 PubMed DOI PMC

Weisel JW, Litvinov RI. Fibrin Formation, Structure and Properties. Subcell Biochem. 2017;82:405–456. doi:10.1007/978-3-319-49674-0_13 PubMed DOI PMC

Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96(12):3772–3778. doi:10.1182/blood.v96.12.3772.h8003772_3772_3778 PubMed DOI

Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem. 1998;273(13):7554–7559. doi:10.1074/JBC.273.13.7554 PubMed DOI

Bacakova M, Musilkova J, Riedel T, et al. The potential applications of fibrin-coated electrospun polylactide nanofibers in skin tissue engineering. Int J Nanomedicine. 2016;11:771–789. doi:10.2147/IJN.S99317 PubMed DOI PMC

Blanquer A, Musilkova J, Filova E, et al. The Effect of a Polyester Nanofibrous Membrane with a Fibrin-Platelet Lysate Coating on Keratinocytes and Endothelial Cells in a Co-Culture System. Nanomater. 2021;11(2):457. doi:10.3390/NANO11020457 PubMed DOI PMC

Tan P, Chan C, Xue S, et al. Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. Atherosclerosis. 2004;173(2):171–183. doi:10.1016/J.ATHEROSCLEROSIS.2003.12.011 PubMed DOI

Táborská J, Riedelová Z, Brynda E, Májek P, Riedel T. Endothelialization of an ePTFE vessel prosthesis modified with an antithrombogenic fibrin/heparin coating enriched with bound growth factors. RSC Adv. 2021;11(11):5903–5913. doi:10.1039/d1ra00053e PubMed DOI PMC

Riedel T, Brynda E, Dyr JE, Houska M. Controlled preparation of thin fibrin films immobilized at solid surfaces. J Biomed Mater Res Part A. 2009;88A(2):437–447. doi:10.1002/jbm.a.31755 PubMed DOI

Augustine R, Dominic EA, Reju I, Kaimal B, Kalarikkal N, Thomas S. Electrospun poly(ε-caprolactone)-based skin substitutes: in vivo evaluation of wound healing and the mechanism of cell proliferation. J Biomed Mater Res Part B Appl Biomater. 2015;103(7):1445–1454. doi:10.1002/JBM.B.33325 PubMed DOI

Jeong SI, Jun ID, Choi MJ, Nho YC, Lee YM, Shin H. Development of electroactive and elastic nanofibers that contain polyaniline and poly(L-lactide-co-epsilon-caprolactone) for the control of cell adhesion. Macromol Biosci. 2008;8(7):627–637. doi:10.1002/MABI.200800005 PubMed DOI

Riedelová-Reicheltová Z, Brynda E, Riedel T. Fibrin nanostructures for biomedical applications. Physiol Res. 2016;65(S2):S263–S272. doi:10.33549/physiolres.933428 PubMed DOI

Perttilä J, Salo M, Peltola O. Plasma fibronectin concentrations in blood products. Intensive Care Med. 1990;16(1):41–43. doi:10.1007/BF01706323 PubMed DOI

Lenselink EA. Role of fibronectin in normal wound healing. Int Wound J. 2015;12(3):313–316. doi:10.1111/IWJ.12109 PubMed DOI PMC

Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci. 2013;110(12):4563. doi:10.1073/PNAS.1221602110 PubMed DOI PMC

Johnson MB, Pang B, Gardner DJ, et al. Topical fibronectin improves wound healing of irradiated skin. Sci Rep. 2017;7(1):3876. doi:10.1038/S41598-017-03614-Y PubMed DOI PMC

Qiu Z, Kwon AH, Kamiyama Y. Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats. J Surg Res. 2007;138(1):64–70. doi:10.1016/J.JSS.2006.06.034 PubMed DOI

Abdul S, Leebeek FWG, Rijken DC, De Willige SU. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences. Blood. 2016;127(5):538–545. doi:10.1182/BLOOD-2015-09-670117 PubMed DOI

Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. Biochemistry. 2010;49(35):7643–7651. doi:10.1021/BI1010317 PubMed DOI PMC

Sulniute R, Shen Y, Guo Y-Z, et al. Plasminogen is a critical regulator of cutaneous wound healing. Thromb Haemost. 2017;116(05):1001–1009. doi:10.1160/TH15-08-0653 PubMed DOI

Hoffman R, Starkey S, Coad J. Wound fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes. J Invest Dermatol. 1998;111(6):1140–1144. doi:10.1046/J.1523-1747.1998.00429.X PubMed DOI

Losi P, Al KT, Buscemi M, Foffa I, Cavallo A, Soldani G. Bilayered fibrin-based electrospun-sprayed scaffold loaded with platelet lysate enhances wound healing in a diabetic mouse model. Nanomater. 2020;10(11):2128. doi:10.3390/NANO10112128 PubMed DOI PMC

Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost. 2000;83(5):736–741. doi:10.1055/S-0037-1613902 PubMed DOI

Crafts TD, Jensen AR, Blocher-Smith EC, Markel TA. Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine. 2015;71(2):385–393. doi:10.1016/J.CYTO.2014.08.005 PubMed DOI

Park JW, Hwang SR, Yoon IS. Advanced growth factor delivery systems in wound management and skin regeneration. Molecules. 2017;22:8. doi:10.3390/MOLECULES22081259 PubMed DOI PMC

Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164(6):1935–1947. doi:10.1016/S0002-9440(10)63754-6 PubMed DOI PMC

Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen. 2014;22(5):569–578. doi:10.1111/WRR.12205 PubMed DOI PMC

Certelli A, Valente P, Uccelli A, et al. Robust Angiogenesis and Arteriogenesis in the Skin of Diabetic Mice by Transient Delivery of Engineered VEGF and PDGF-BB Proteins in Fibrin Hydrogels. Front Bioeng Biotechnol. 2021;9:688467. doi:10.3389/fbioe.2021.688467 PubMed DOI PMC

Hanft JR, Pollak RA, Barbul A, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care. 2008;17(1):30–2,34–7. doi:10.12968/JOWC.2008.17.1.27917 PubMed DOI

Martí-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015;2015(10):CD008548. doi:10.1002/14651858.CD008548.PUB2 PubMed DOI PMC

Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol. 1990;136(6):1235. PubMed PMC

Akita S, Akino K, Imaizumi T, Hirano A. Basic fibroblast growth factor accelerates and improves second-degree burn wound healing. Wound Repair Regen. 2008;16(5):635–641. doi:10.1111/J.1524-475X.2008.00414.X PubMed DOI

Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol. 2003;162(1):303–312. doi:10.1016/S0002-9440(10)63821-7 PubMed DOI PMC

Thangarajah H, Yao D, Chang EI, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci. 2009;106(32):13505–13510. doi:10.1073/PNAS.0906670106 PubMed DOI PMC

Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22(4):201–207. doi:10.1016/S0165-6147(00)01676-X PubMed DOI

Chiu A, Sharma D, Zhao F. Tissue Engineering-Based Strategies for Diabetic Foot Ulcer Management. Adv Wound Care. 2023;12(3):145–167. doi:10.1089/wound.2021.0081 PubMed DOI PMC

Zhang S, Ge G, Qin Y, et al. Recent advances in responsive hydrogels for diabetic wound healing. Mater Today Bio. 2023;18:100508. doi:10.1016/j.mtbio.2022.100508 PubMed DOI PMC

Chen Z, Wu H, Wang H, et al. An injectable anti-microbial and adhesive hydrogel for the effective noncompressible visceral hemostasis and wound repair. Mater Sci Eng. 2021;129:112422. doi:10.1016/j.msec.2021.112422 PubMed DOI

Li J, Gao H, Xiong Y, et al. Enhancing Cutaneous Wound Healing Based on Human Induced Neural Stem Cell-derived Exosomes. Int J Nanomedicine. 2022;17:5991–6006. doi:10.2147/IJN.S377502 PubMed DOI PMC

Qin W, Wu Y, Liu J, et al. A Comprehensive Review of the Application of Nanoparticles in Diabetic Wound Healing: therapeutic Potential and Future Perspectives. Int J Nanomedicine. 2022;17:6007–6029. doi:10.2147/IJN.S386585 PubMed DOI PMC